Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HCK | P08631 | 1/20 | 0.60 |
| ▸ | NR2C2 | P49116 | 1/20 | 0.60 |
| ▸ | HTT | P42858 | 2/20 | 0.60 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.60 |
| ▸ | ATM | Q13315 | 1/20 | 0.60 |
| ▸ | MAPK14 | Q16539 | 4/20 | 0.58 |
| ▸ | MAP3K7 | O43318 | 3/20 | 0.58 |
| ▸ | MAP4K2 | Q12851 | 3/20 | 0.58 |
| ▸ | MAP3K20 | Q9NYL2 | 1/20 | 0.58 |
| ▸ | FES | P07332 | 1/20 | 0.56 |
| ▸ | FER | P16591 | 1/20 | 0.56 |
| ▸ | EGFR | P00533 | 1/20 | 0.56 |
| ▸ | BRAF | P15056 | 1/20 | 0.56 |
| ▸ | KIT | P10721 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14689664 | 0.90 | RAD52 (0.60) | HCKNR2C2HTTMAPK1ATM | |
| SCHEMBL2280193 | 0.84 | RAD52 (0.75) | HCKNR2C2HTTMAPK1ATM | |
| SCHEMBL17208738 | 0.82 | RAD52 (0.71) | HCKNR2C2HTTMAPK1ATM | |
| SCHEMBL2226481 | 0.81 | HTT (0.68) | HCKNR2C2HTTMAPK1ATM | |
| SCHEMBL2284124 | 0.80 | MAPK14 (0.75) | ATMMAPK14MAP3K7MAP4K2MAP3K20 | |
| SCHEMBL2282784 | 0.80 | MAPK14 (0.61) | ATMMAPK14MAP3K7MAP4K2MAP3K20 | |
| SCHEMBL2278939 | 0.80 | MAPK14 (0.61) | ATMMAPK14MAP3K7MAP4K2MAP3K20 | |
| SCHEMBL3389535 | 0.80 | HTT (0.71) | HCKNR2C2HTTMAPK1ATM | |
| SCHEMBL17208687 | 0.78 | MAPK14 (0.56) | HCKNR2C2HTTMAPK1ATM | |
| SCHEMBL4254623 | 0.78 | HTT (0.64) | HCKNR2C2HTTMAPK1ATM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11826365-B2 | Type II raf kinase inhibitors | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2023-11-28 | — | — | US | disclosed |
| US-20200297721-A1 | TYPE II RAF KINASE INHIBITORS | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2020-09-24 | — | — | US | disclosed |
| EP-2937345-B1 | TYPE II RAF KINASE INHIBITORS | DANA FARBER CANCER INST INC (US) | 2018-03-21 | — | — | EP | disclosed |
| US-9358231-B2 | Type II RAF kinase inhibitors | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2016-06-07 | — | — | US | disclosed |
| US-20160046636-A1 | TYPE II RAF KINASE INHIBITORS | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2016-02-18 | — | — | US | disclosed |
| US-9180127-B2 | Type II Raf kinase inhibitors | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2015-11-10 | — | — | US | disclosed |
| EP-2937345-A2 | Type II raf kinase inhibitors | Dana-Farber Cancer Institute, Inc. (US) | 2015-10-28 | — | — | EP | disclosed |
| US-20150157629-A1 | TYPE II RAF KINASE INHIBITORS | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2015-06-11 | — | — | US | disclosed |
| EP-2519517-B1 | TYPE II RAF KINASE INHIBITORS | DANA FARBER CANCER INST INC (US) | 2015-03-25 | — | — | EP | disclosed |
| US-20130040949-A1 | TYPE II RAF KINASE INHIBITORS | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2013-02-14 | — | — | US | disclosed |
| EP-2519517-A2 | TYPE II RAF KINASE INHIBITORS | Dana-Farber Cancer Institute, Inc. (US) | 2012-11-07 | — | — | EP | disclosed |
| WO-2011090738-A2 | TYPE II RAF KINASE INHIBITORS | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2011-07-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11826365-B2 | Type II raf kinase inhibitors | BRAF, RAF1, ARAF | HCK 495/4885NR2C2 1110/4885HTT 3884/4885 |
| US-20150157629-A1 | TYPE II RAF KINASE INHIBITORS | BRAF, RAF1, ARAF | HCK 495/4885NR2C2 1110/4885HTT 3884/4885 |
| US-20200297721-A1 | TYPE II RAF KINASE INHIBITORS | BRAF, RAF1, ARAF | HCK 495/4885NR2C2 1110/4885HTT 3884/4885 |
| US-20160046636-A1 | TYPE II RAF KINASE INHIBITORS | BRAF, RAF1, ARAF | HCK 495/4885NR2C2 1110/4885HTT 3884/4885 |
| US-20130040949-A1 | TYPE II RAF KINASE INHIBITORS | BRAF, RAF1, ARAF | HCK 495/4885NR2C2 1110/4885HTT 3884/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.